glp 1 effect on kidneys Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side Potential kidney-protective and other effects

Systemic inflammation markers (CRP, ESR) should show measurable improvement on bloodwork if they were elevated at baseline

Combining them may offer complementary glucose-lowering effects for patients who need additional glycemic control

Similar content being viewed by others Introduction Type 2 diabetes (T2D) is the leading cause of end-stage kidney disease (ESKD) globally [1]

During consultation, notice whether providers ask detailed questions about your health, lifestyle, and goals, explain treatment rationale and expected outcomes clearly, discuss potential side effects and management strategies openly, and provide written protocols with detailed instructions

10.2337/db16-1009 134